World Health Organization Raises Warning Over Severe Shortage of Weight-Loss Injections
Less than 10% of patients that would benefit from obesity jabs including Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with thorough and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the injections that can assist patients in reducing significant body mass, notes the body.
GLP-1 Therapy Shortage
Even in the current best projected case, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on countries and companies to expand availability, by strategies like patent sharing.
The intellectual property rights on a key compound – the core component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and increase the sense of being full so users eat less.
People typically see weight reduction after several weeks of beginning the weekly injections.
Evidence points to users may put most of the weight back on after a year of stopping the treatment, as their usual food cravings resume.
Being carrying excess weight raises your likelihood for experiencing medical conditions, including diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects individuals in every country and was linked to millions of deaths worldwide in 2024, per the WHO.
